Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Tyenne 20 mg/mL concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
tocilizumab
Company:  
Fresenius Kabi Ltd See contact details
ATC code: 
L04AC07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Tyenne (tocilizumab) Dosing Guide

{healthcare_pro_orange} For Healthcare Professionals

A guide to assist healthcare professionals with the dose preparation and administration of TYENNE therapy

{pdf_link}

Tyenne (tocilizumab) Healthcare Professional Brochure

{healthcare_pro_orange} For Healthcare Professionals
This material is provided by Fresenius Kabi Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan
{pdf_link}

Tyenne (tocilizumab) Important Safety Information for Patients

Important safety information for patients and their caregivers understand the use of Tyenne (tocilizumab) therapy
{pdf_link}

Tyenne (tocilizumab) Patient Alert Card

Patient alert card to help patients understand the risks associated with Tyenne (tocilizumab)

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Fresenius Kabi Ltd
Company image
Address
Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT
Telephone
+44 (0)1928 533 533
Fax
+44 (0)1928 533 420
Medical Information Direct Line
+44 (0)1928 533 575
Medical Information e-mail
[email protected]
Stock Availability
[email protected]
Customer Care direct line
+44 (0)1928 533 533
Medical Information Fax
+44 (0)1928 533 587
WWW
https://www.fresenius-kabi.com/gb/